📰 Gene Therapy Program News
Page 5 - Gene Therapy Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Gene Therapy Program. Real-time updates on events, politics, business and more.
August 7, 2023
Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF...
July 31, 2023
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS)
June 13, 2023
Passage Bio (NASDAQ:PASG – Get Rating) and Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership. Earnings and Valuation This table compares Passage Bio and […]
May 12, 2023
Relive the Class of 2023s junior year, in which the University transitioned back to in-person life and Liz Magill became the Universitys ninth president.
May 9, 2023
- Program Updates Planned for Azer-cel and PBCAR19B in May 2023 - Presented data on PBGENE-HBV program at Global Hepatitis Summit 2023; PBGENE-DMD program data update upcoming at ASGCT... | May 9, 2023
April 28, 2023
Aziyo Biologics (NASDAQ:AZYO – Get Rating) and Passage Bio (NASDAQ:PASG – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations. Profitability This table compares Aziyo Biologics and Passage Bio’s […]
April 21, 2023
PHILADELPHIA, April 21, 2023 -- Passage Bio, Inc. , a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced... | April 21, 2023
April 12, 2023
The Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization (CDMO) dedicated to addressing critical challenges associated with the commercialization of cell and gene therapies, has completed a successful...
March 31, 2023
A novel coronavirus would come to affect every ward, clinician, researcher and patient at Massachusetts General Hospital.
March 27, 2023
PHILADELPHIA, March 27, 2023 -- Passage Bio, Inc. , a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced... | March 27, 2023